Sulfasalazine blocks the development of tactile allodynia in diabetic rats

Diabetes

Volumn 57, Issue 10, 2008, Pages 2801-2808

  Berti Mattera, Liliana N ^a   Kern, Timothy S ^a,b   Siegel, Ruth E ^a   Nemet, Ina ^a   Mitchell, Rochanda ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSINE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P50; SALAZOSULFAPYRIDINE; SALICYLATE SODIUM; STREPTOZOCIN; N (OXO 5,6 DIHYDROPHENANTHRIDIN 2 YL) N,N DIMETHYLACETAMIDE HYDROCHLORIDE; N-(OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)-N,N-DIMETHYLACETAMIDE HYDROCHLORIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENANTHRENE DERIVATIVE; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIAGNOSTIC TEST; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GANGLION BLOCK; GLUCOSE BLOOD LEVEL; IMMUNOBLOTTING; LEWIS RAT; MOUSE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCIATIC NERVE; SPINAL GANGLION; STREPTOZOCIN DIABETES; TACTILE ALLODYNIA; ANIMAL; BLOOD; BODY WEIGHT; EXPERIMENTAL DIABETES MELLITUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; GANGLIA, SPINAL; IMMUNOBLOTTING; INOSINE; NF-KAPPA B P50 SUBUNIT; PAIN; PAIN MEASUREMENT; PHENANTHRENES; RATS; SALICYLATES; SCIATIC NERVE; SULFASALAZINE; TANDEM MASS SPECTROMETRY;

EID: 58149335418     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1274     Document Type: Article

References (38)

1. Vinik AT, Park TS, Stansberry KB, Pittenger GL: Diabetic neuropathies. Diabetologia 43:957-973, 2000
2. Calcutt NA, Freshwater JD, Mizisin AP: Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47:718-724, 2004
3. Shutov L, Kruglikov T, Gryshchenko O, Khomula E, Viatchenko-Karpin-ski V, Belan P, Voitenko N: The effect of nimodipine on calcium homeostasis and pain sensitivity in diabetic rats. Cell Mol Neurobiol 26:1541-1557, 2006
4. Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163-1174, 1998
5. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of TkappaB kinases alpha and beta. Gastroenterology 119:1209-1218, 2000
6. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56:337-345, 2007
7. Gadangi P, Longaker M, Naime D, Levin RT, Recht PA, Montesinos MC, Buckley MT, Carlin G, Cronstein BN: The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156:1933-1941, 1996
8. Cronstein BN, Montesinos MC, Weissmann G: Salicylates and sulfasala-zine, but not glucocorticoids, inhibit leukocyte accumulation by an ade-nosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci USA 96:6377-6381, 1999
9. Carlin G, Djursater R, Smedegard G: Tnhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonu-clear leukocytes. Pharmacol Toxicol 65:121-127, 1989
10. Tornhamre S, Edenius C, Smedegard G, Sjouist B, Lindgren JA: Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygen-ase and cyclooxygenase products. Eur J Pharmacol 169:225-234, 1989
11. Bradley SM, le Gallez P, Throughton PR, Gooi HC, Astbury C, Bird HA: The effect of sulphasalazine on neutrophil superoxide generation in rheumatoid arthritis. Br J Rheumatol 36:530-534, 1997
12. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Tnhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Bio-chem Pharmacol 53:1901-1907, 1997
13. Zheng L, Szabó C, Kern TS: Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-KB. Diabetes 53:2960-2967, 2004
14. Sha WC, Liou HC, Tuomanen ET, Baltimore D: Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80:321-330, 1995
15. Berti-Mattera LN, Gariepy CE, Burke R, Hall AK: Reduced expression of endothelin B receptors and mechanical hyperalgesia in experimental chronic diabetes. Exp Neurol 201:399-406, 2006
16. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63, 1994
17. Joseph SM, Pifer MA, Przybylski RJ, Dubyak, GR: Methylene ATP analogs as modulators of extracellular ATP metabolism and accumulation. Br J Pharmacol 142:1002-1014, 2004
18. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR: Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68:293-299, 1996
19. Obrosova TG, Li F, Abatan OT, Forsell MA, Komjati K, Pacher P, Szabo C, Stevens MJ: Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53:711-720, 2004
20. Li F, Szabó C, Pacher P, Southan GJ, Abatan OT, Charniauskaya T, Stevens MJ, Obrosova TG: Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 47:710-717, 2004
21. Tlnystka O, Lyzogubov VV, Stevens MJ, Drel VR, Mashtalir N, Pacher P,Yorek MA, Obrosova TG: Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 55:1686-1694, 2006
22. Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA: Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res 1:131-143, 2000
23. Roytta M, Wei H, Pertovaara A: Spinal nerve ligation-induced neuropathy in the rat: sensory disorders and correlation between histology of the peripheral nerves. Pain 80:161-170, 1999
24. Cameron NE, Cotter MA: The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes. Exp Neurol 207:23-29, 2007
25. Tegeder T, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M, Geisslinger G: Specific Tnhibition of TkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neu-rosci 24:1637-1645, 2004
26. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AA, Andrassy M, Schiekofer S, Schneider JG, Schulz JB, Heuss D, Neundörfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Haering HU, Schleicher E, Kasper M, Stern DM, Arnold B, Nawroth PP: Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 114:1741-1751, 2004
27. Purves TD, Tomlinson DR: Diminished transcription factor survival signals in dorsal root ganglia in rats with streptozotocin-induced diabetes. Ann N Y Acad Sci 973:472-476, 2002
28. Doyle CA, Hunt SP: Reduced nuclear factor kappaB (p65) expression in rat primary sensory neurons after peripheral nerve injury. Neuroreport 8:2937-2942, 1997
29. Nickols JC, Valentine W, Kanwal S, Carter BD: Activation of the transcription factor NF-kappaB in Schwann cells is required for peripheral myelin formation. Nat Neurosci 6:161-167, 2003
30. Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, Green EJ, Bethea JR: Tnhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med 202:145-156, 2005
31. Lynch JJ, Jarvis MF, Kowaluk EA: An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain. Eur J Pharmacol 364:141-146, 1999
32. Saini AK, Arun KH, Kaul CL, Sharma SS: Acute hyperglycemia attenuates nerve conduction velocity and nerve blood flow in male Sprague-Dawley rats: reversal by adenosine. Pharmacol Res 50:593-599, 2004
33. Cui JG, Sollevi A, Linderoth B, Meyerson BA: Adenosine receptor activation suppresses tactile hypersensitivity and potentiates spinal cord stimulation in mononeuropathic rats. Neurosci Lett 223:173-176, 1997
34. Sawynok J, Liu XJ: Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 69:313-340, 2003
35. Benowitz LI, Jing Y, Tabibiazar R, Jo SA, Petrausch B, Stuermer CA, Rosenberg PA, Irwin N: Axon outgrowth is regulated by an intracellular purine-sensitive mechanism in retinal ganglion cells. J Biol Chem 273: 29626-29634, 1998
36. Chen P, Goldberg DE, Kolb B, Lanser M, Benowitz LI: Inosine induces axonal rewiring and improves behavioral outcome after stroke. Proc Natl Acad SciUSA 99:9031-9036, 2002
37. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552, 2001
38. Gwag BJ, Lee YA, Ko SY, Lee MJ, Im DS, Yun BS, Lim HR, Park SM, Byun HY, Son SJ, Kwon HJ, Lee JY, Cho JY, Won SJ, Kim KW, Ahn YM, Moon HS, Lee HU, Yoon SH, Noh JH, Chung JM, Cho SI: Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab 27:1142-1151, 2007